• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALLERGAN (PRINGY) JUVEDERM ULTRA PLUS XC TSK US; IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALLERGAN (PRINGY) JUVEDERM ULTRA PLUS XC TSK US; IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Catalog Number 94155
Device Problem Improper or Incorrect Procedure or Method (2017)
Patient Problems Skin Inflammation (2443); Pallor (2468); Vascular System (Circulation), Impaired (2572)
Event Date 12/18/2018
Event Type  Injury  
Manufacturer Narrative
(b)(4).The events of "blanching", "because of the blood pressure behind the occlusion, it burst a vessel and it leaked", and "white heads" are physiological complications and analysis of the device generally does not assist allergan in determining a probable cause for these events.Further information from the reporter regarding event, product, or patient details has been requested.No additional information is available at this time.This is a known potential adverse event addressed in the product labeling.
 
Event Description
Healthcare professional reported injecting a patient in the lips with half a syringe of juvéderm® ultra plus xc.The injector reported diluting the filler with.3cc of lidocaine to make it runnier.The injector reported noticed blanching immediately during injection and took the syringe out.The patient was treated with hyaluronidase ¿immediately¿ and ¿because of the blood pressure behind the occlusion, it burst a vessel and it leaked.¿ the patient began using arnica.The patient came back the next day was treated with 10 units of hyaluronidase.It was ¿still blanching¿ and the injector could not tell if it was occluded or bruised¿ and it ¿still looked like there was color in there.¿ the next day, the injector noted that the area was "slightly darker and there were white heads." the patient was given more hyaluronidase.Patient had been taking biotin, omega 3, and multivitamins daily, but stopped taking them a few days before injection.The symptoms have not resolved.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
JUVEDERM ULTRA PLUS XC TSK US
Type of Device
IMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
ALLERGAN (PRINGY)
route de promery
zone artisanale de pre-mairy
pringy 74370
FR  74370
Manufacturer (Section G)
ALLERGAN (PRINGY)
route de promery
zone artisanale de pre-mairy
pringy 74370
FR   74370
Manufacturer Contact
suzanne wojcik
301 w howard lane
suite 100
austin, TX 78753
7372473605
MDR Report Key8260268
MDR Text Key133487768
Report Number3005113652-2019-00011
Device Sequence Number1
Product Code LMH
UDI-Device Identifier30888628000111
UDI-Public30888628000111
Combination Product (y/n)N
PMA/PMN Number
P050047
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Nurse
Type of Report Initial
Report Date 01/18/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date12/01/2019
Device Catalogue Number94155
Device Lot NumberH30LA80476
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 12/20/2018
Initial Date FDA Received01/18/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured07/01/2018
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age31 YR
-
-